Lantheus Continues to Commend CMS’ CY25 Rule to Enhance Payment for Specialized Diagnostic Radiopharmaceuticals and Reaffirms Outlook for PYLARIFY’s Blockbuster Status for 2025
Lantheus Holdings (NASDAQ: LNTH) responds to CMS' updated payment rates for Calendar Year 2025 Medicare Hospital Outpatient Prospective Payment System. The new rules will 'unbundle' diagnostic radiopharmaceuticals, enabling separate payments for those costing over $630 per day. This change affects approximately 20% of traditional Medicare Fee for Service patients in hospital outpatient settings. PYLARIFY®, the company's PSMA PET imaging agent, is expected to exceed $1 billion in sales in 2024 and maintain its position as the #1 ordered PSMA PET imaging agent in the U.S. The new payment system will be effective January 1, 2025.
Lantheus Holdings (NASDAQ: LNTH) risponde ai tassi di pagamento aggiornati del CMS per l'anno solare 2025 del Sistema di Pagamento Prospective per Ospedali Medicare. Le nuove regole 'separano' i radiofarmaci diagnostici, consentendo pagamenti separati per quelli che costano oltre 630 dollari al giorno. Questa modifica interessa circa il 20% dei pazienti tradizionali di Medicare con servizio a pagamento in contesti ambulatoriali ospedalieri. PYLARIFY®, l'agente di imaging PSMA PET dell'azienda, è previsto superare il miliardo di dollari di vendite nel 2024 e mantenere la sua posizione come l'agente di imaging PSMA PET più ordinato negli Stati Uniti. Il nuovo sistema di pagamento entrerà in vigore il 1 gennaio 2025.
Lantheus Holdings (NASDAQ: LNTH) responde a las tasas de pago actualizadas del CMS para el Año Calendario 2025 del Sistema de Pago Prospectivo para Hospitales de Medicare. Las nuevas reglas 'desagregan' los radiofármacos diagnósticos, permitiendo pagos separados para aquellos que costan más de 630 dólares por día. Este cambio afecta aproximadamente al 20% de los pacientes tradicionales de Medicare en servicios ambulatorios hospitalarios. PYLARIFY®, el agente de imágenes PSMA PET de la empresa, se espera que supere los 1,000 millones de dólares en ventas en 2024 y mantenga su posición como el agente de imágenes PSMA PET más solicitado en EE. UU. El nuevo sistema de pago será efectivo a partir del 1 de enero de 2025.
Lantheus Holdings (NASDAQ: LNTH)는 2025년도 Medicare 병원 외래 진료 예측 지불 시스템을 위한 CMS의 업데이트된 지불 요율에 대응합니다. 새로운 규칙은 진단 방사성 의약품을 '구분'하여 하루에 630달러 이상 비용이 드는 경우 각각의 지불을 가능하게 합니다. 이 변화는 병원 외래 진료 환경에서 전통적인 Medicare 서비스 이용 환자의 약 20%에 영향을 미칩니다. PYLARIFY®는 회사의 PSMA PET 이미징 제제로 2024년에 10억 달러 이상의 매출을 기록할 것으로 예상되며, 미국에서 가장 많이 주문되는 PSMA PET 이미징 제제로 그 위치를 유지할 것입니다. 새로운 지불 시스템은 2025년 1월 1일부터 효력을 발휘합니다.
Lantheus Holdings (NASDAQ: LNTH) répond aux taux de paiement mis à jour par le CMS pour l'année calendrier 2025 du Système de Paiement Prospectif pour les Patients Hospitaliers de Medicare. Les nouvelles règles vont 'découpler' les radiopharmaceutiques diagnostiques, permettant des paiements séparés pour ceux coûtant plus de 630 dollars par jour. Ce changement concerne environ 20 % des patients traditionnels de Medicare en service de paiement dans les établissements hospitaliers. PYLARIFY®, l'agent d'imagerie PSMA PET de l'entreprise, devrait dépasser 1 milliard de dollars de ventes en 2024 et maintenir sa position de l'agent d'imagerie PSMA PET le plus commandé aux États-Unis. Le nouveau système de paiement sera en vigueur à partir du 1er janvier 2025.
Lantheus Holdings (NASDAQ: LNTH) reagiert auf die aktualisierten Zahlungssätze von CMS für das Kalenderjahr 2025 im Rahmen des Medicare Krankenhaus-Außenpatienten-Pauschalen-Systems. Die neuen Vorschriften werden diagnostische Radiopharmazeutika 'entkoppeln' und ermöglichen separate Zahlungen für diejenigen, die mehr als 630 US-Dollar pro Tag kosten. Diese Änderung betrifft etwa 20 % der traditionellen Medicare-Patienten im ambulanten Krankenhausbereich. PYLARIFY®, das PSMA PET-Bildgebungsinstrument des Unternehmens, wird voraussichtlich im Jahr 2024 Verkäufe von über 1 Milliarde US-Dollar erzielen und seine Position als das am häufigsten bestellte PSMA PET-Bildgebungsinstrument in den USA halten. Das neue Zahlungssystem tritt am 1. Januar 2025 in Kraft.
- PYLARIFY expected to exceed $1 billion in sales in 2024
- Maintains position as #1 ordered PSMA PET imaging agent in U.S.
- New CMS payment system ensures continued separate reimbursement for PYLARIFY
- None.
Insights
The CMS policy change for 2025 represents a significant positive development for Lantheus and the radiopharmaceutical industry. The "unbundling" of diagnostic radiopharmaceuticals with costs exceeding
PYLARIFY's projected
BEDFORD, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, notes that the Centers for Medicare & Medicaid Services (CMS) recently posted updated payment rates in Addendum B related to the final rule for the calendar year 2025 Medicare Hospital Outpatient Prospective Payment System (OPPS). The Company continues to commend CMS for recognizing the value of and ensuring broad patient access to specialized diagnostic radiopharmaceuticals. With PYLARIFY® (piflufolastat F 18) on track to exceed
Under the new OPPS rules, previously packaged diagnostic radiopharmaceuticals will now be “unbundled” with payments being made separately for any diagnostic radiopharmaceutical with a per day cost greater than
About PYLARIFY® (piflufolastat F 18) Injection
PYLARIFY® (piflufolastat F 18) injection (also known as 18F-DCFPyL or PyL) is a fluorinated small molecule PSMA-targeted PET imaging agent that enables visualization of lymph nodes, bone and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. For men with prostate cancer, PYLARIFY PET combines the accuracy of PET imaging, the precision of PSMA targeting and the clarity of an F 18 radioisotope for superior diagnostic performance. The recommended PYLARIFY dose is 333 MBq (9 mCi) with an acceptable range of 296 MBq to 370 MBq (8 mCi to 10 mCi), administered as a bolus intravenous injection.1-6
PYLARIFY has made a profound impact on the lives of patients battling prostate cancer. It is the number one ordered PSMA PET imaging agent in the U.S., and is a proven diagnostic backed by real-world experience, including in over 400,000 scans across 48 states.
PYLARIFY® (piflufolastat F 18) Injection
Indication
PYLARIFY® (piflufolastat F 18) Injection is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer:
- with suspected metastasis who are candidates for initial definitive therapy.
- with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.
Important Safety Information
Contraindications
None.
Warnings and Precautions
Risk of Image Misinterpretation
Imaging interpretation errors can occur with PYLARIFY imaging. A negative image does not rule out the presence of prostate cancer and a positive image does not confirm the presence of prostate cancer. The performance of PYLARIFY for imaging of patients with biochemical evidence of recurrence of prostate cancer seems to be affected by serum PSA levels. The performance of PYLARIFY for imaging of metastatic pelvic lymph nodes prior to initial definitive therapy seems to be affected by risk factors such as Gleason score and tumor stage. PYLARIFY uptake is not specific for prostate cancer and may occur with other types of cancer as well as non-malignant processes and in normal tissues. Clinical correlation, which may include histopathological evaluation of the suspected prostate cancer site, is recommended.
Hypersensitivity Reactions
Monitor patients for hypersensitivity reactions, particularly patients with a history of allergy to other drugs and foods. Reactions may be delayed. Always have trained staff and resuscitation equipment available.
Radiation Risks
Diagnostic radiopharmaceuticals, including PYLARIFY, expose patients to radiation. Radiation exposure is associated with a dose-dependent increased risk of cancer. Ensure safe handling and preparation procedures to protect patients and health care workers from unintentional radiation exposure. Advise patients to hydrate before and after administration and to void frequently after administration.
Adverse Reactions
The most frequently reported adverse reactions were headaches, dysgeusia and fatigue, occurring at rate of ≤
Drug interactions
Androgen deprivation therapy (ADT) and other therapies targeting the androgen pathway, such as androgen receptor antagonists, may result in changes in uptake of PYLARIFY in prostate cancer. The effect of these therapies on performance of PYLARIFY PET has not been established.
To report suspected adverse reactions for PYLARIFY, call 1-800-362-2668 or contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please read the accompanying full Prescribing Information also available at PYLARIFY.com.
About Lantheus
Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in Canada and Sweden, Lantheus has been providing radiopharmaceutical solutions for more than 65 years. For more information, visit www.lantheus.com.
Safe Harbor for Forward-Looking and Cautionary Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks and uncertainties and are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by their use of terms such as “will,” “continue,” “outlook” and other similar terms. Such forward-looking statements, include statements regarding expected PYLARIFY blockbuster status and ranking in the market, and are based upon current plans, estimates and expectations that are subject to risks and uncertainties that could cause actual results to materially differ from those described in the forward-looking statements. These uncertainties include our ability to continue market expansion and penetration for PYLARIFY in a competitive environment in which other imaging agents have been approved and are being commercialized. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Readers are cautioned not to place undue reliance on the forward-looking statements contained herein, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements are discussed in our filings with the Securities and Exchange Commission (including those described in the Risk Factors section in our Annual Reports on Form 10-K and our Quarterly Reports on Form 10-Q).
1Tan N, Oyoyo U, Bavadian N, et al. PSMA-targeted radiotracers versus 18F fluciclovine for the detection of prostate cancer biochemical recurrence after definitive therapy: a systematic review and meta-analysis. Radiology. 2020;296:44-55. doi:10.1148/radiol.2020191689.
2Mena et al. 18 F-DCFPyL PET/CT Imaging in Patients with Biochemically Recurrent Prostate Cancer After Primary Local Therapy J Nucl Med 2020 Jun;61(6):881-889. doi: 10.2967/jnumed.119.234799. Epub 2019 Nov 1.
3Alipour et al. Guiding management of therapy in prostate cancer: time to switch from conventional imaging to PSMA PET? Ther Adv Med Oncol. 2019; 11: 1758835919876828.
4Werner et al 18F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging Theranostics 2020; 10(1):1-16. doi:10.7150/thno.37894.
5Petersen LJ, Zacho HD. PSMA PET for primary lymph node staging of intermediate and high-risk prostate cancer: an expedited systematic review. Cancer Imaging. 2020;20(1):1-8. doi:10.1186/s40644-020-0290
6PYLARIFY® [package insert]. North Billerica, MA: Progenics Pharmaceuticals, Inc., a Lantheus company.
Contacts:
Mark Kinarney
Vice President, Investor Relations
978-671-8842
ir@lantheus.com
Melissa Downs
Senior Director, External Communications
646-975-2533
media@lantheus.com
FAQ
What is the expected sales forecast for Lantheus' PYLARIFY (LNTH) in 2024?
When will the new CMS payment rules affecting Lantheus (LNTH) take effect?